BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis

real time PCR for t(9;22) BCR-ABL1 p210 (e13a2/e14a2) fusion gene
Lab Test name Contact Comments
AZ St-Jan Brugge - Laboratoriumgeneeskunde BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis dr. Helena Devos/Friedel Nollet, Ph.D.
Real time PCR; RNA-test
primers from EAC consortium, Gabert et al. Leukemia (2003)
Version date: 04/11/2017
IPG Gosselies BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis P. Vannuffel
C. De Rop
Quantitative RT-PCR with ipsogen BCR-ABL1 Mbcr IS-MMR kit (QIAGEN).

Sample type: Blood and bone marrow.
BELAC accreditation number: 381-MED.
UZ Gent BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Barbara Denys,
Karl Vandepoele
Real-time PCR with EAC primers,
based on Gabert et al, Leukemia 2003;
BELAC accreditation number 087-MED
Version date: 16/03/2021
UZA Mol. Diagn. BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis K. Vermeulen,
M. Le Mercier,
M-B Maes
Quantitative RT-PCR with EAC protocol (Gabert et al, Leukemia 2003; Beillard et al. Leukemia, 2003) with de BCR-ABL Mbcr Fusionquant Kit (Ipsogen) on Lightcycler 480
Sample type: blood / bone marrow
BELAC accreditation number 204-MED
Version date: 06/09/2022
UZ Brussel - Molecular Hematology BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Marleen Bakkus/Barbara Depreter
Sample type: 4 ml EDTA blood, 2 ml EDTA bone marrow
Transport: room temperature, within 72h after sampling
Frequency: 3x/week
CE-IVD kit: Xpert® BCR-ABL Ultra (Cepheid)
BELAC accreditation number: 141-MED
Version date: 12/04/2023
CHU Liège - Hemato BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Dr Frédéric Lambert
Kit CE ipsogen BCR-ABL1 Mbcr IS-MMR - QIAGEN

BELAC accreditation number: 128-MED
Jessa Hospital BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Dr. Brigitte Maes, Ellen Geerdens
Blood or bone marrow (1ml, EDTA)
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: 1x/week
TEST TYPE: Real-time RT-PCR, in house method from Gabert et al
LHUB-ULB BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Pierre Heimann/Laurent Dewispelaere/Pascale Cochaux/Hakim El Housni
SAMPLE TYPE: Peripheral blood or bone marrow (EDTA, 1-2 mL)
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: 1x/week; TAT: 2 weeks
TEST TYPE: Real-Time PCR with EAC primers, based on Gabert et al., Leukemia 2003. IS scale
BELAC accreditation number 650-MED
Version date: 04/10/2021
GZA St-Augustinus BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Philippe Van Lint
Real-time PCR with EAC primers,
based on Gabert et al, Leukemia 2003;

Performed on whole blood, or bone marrow (EDTA)

BELAC accreditation number 404-MED
OLVZ Aalst BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Anne Vankeerberghen
Sample type:
EDTA-Blood (min. 10 million WBC) or bone marrow (min. 400 µL)
Frequency: 1/week
Test type: Real time PCR (Europe against cancer Program; Beillard et al, 2003)
Version date: 06/05/2019
AZ St-Lucas Gent BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis DR H. Louagie / Koen Jacobs
-EDTA blood (4ml)
-EDTA bone marrow

FREQUENCY: 1x/2 weeks

TEST TYPE: Ipsogen FusionQuant
UZ Leuven MolPLUZ BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis N. Boeckx, L. Michaux
Sample type:
- EDTA-blood
- EDTA-bone marrow

Minimal sample volume: 4 ml (peripheral blood)
Frequency: every day (Monday to Friday)
Test type: GeneXpert RQ-PCR
AZ Delta BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Elisabeth Moreau/Elke Boone
SAMPLE TYPE: Blood or bone marrow (1ml, EDTA)
FREQUENCY: 1x/2-weeks
TEST TYPE: Real-time RT-PCR, EAC protocol (Gabert et al, leukemia 2003)
Version date: 05/12/2017
ZNA Middelheim BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Pieter De Schouwer
Sample type : bone marrow or EDTA blood
Frequency: once a week
Test type: in house real-time PCR
Labo Cliniques Sud Luxembourg BCR-ABL1 p210 (e13a2/e14a2) quantitative analysis Nicolas Hougardy
- Blood (EDTA) (min 10ml)
- Bone Marrow (EDTA) (min 2,5ml)
!The sample has to stay at 4-8°C during transport!
FREQUENCY: every two weeks
TEST TYPE: In-house, RT-PCR, Real time PCR (Screening of acquired abnormalities in the diagnosis and in the follow-up of CML), LightCycler (Roche)
ARTICLE: "Gabert,leukemia (2003), 17, 2318-57"